Form 4: Leap Therapeutics COO Settles Restricted Stock Units, Adjusts Holdings

Augustine Lawlor, COO of Leap Therapeutics, settled restricted stock units on March 28, 2025, resulting in adjustments to his directly and indirectly held shares of common stock.

Summary

• On March 28, 2025, Augustine Lawlor, the Chief Operating Officer of Leap Therapeutics, settled 22,500 Restricted Stock Units (RSUs) that were granted on January 31, 2022.
• The settlement was executed on a net issue basis, where 14,703 shares were issued to Lawlor, and 7,797 shares were withheld to cover tax obligations.
• The price per share for the tax withholding was $0.3166.
• Lawlor's directly held common stock increased by 14,703 shares due to the RSU settlement, while 7,797 shares were withheld for tax purposes.
• Lawlor also indirectly owns shares through Nine Capital Partners, HealthCare Ventures IX, L.P. (HCV IX), and the HCV VIII Trust.
• The share numbers have been adjusted to reflect a 10-for-1 reverse stock split that occurred on June 20, 2023.
• The Compensation Committee deferred the settlement of the RSUs from the vesting date of January 31, 2025, to March 28, 2025, due to potential insider trading policy restrictions.

Sentiment

Score: 6

Explanation: The document reflects a neutral event (RSU settlement) with no explicit positive or negative implications for the company's performance or outlook. The delay in settlement due to insider trading policy is a minor concern, but overall the sentiment is fairly neutral.

Positives

• The settlement of RSUs indicates that Lawlor has met the vesting requirements, suggesting continued service with the company.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. This filing indicates normal compensation practices and insider activity.

Comparison to Industry Standards

• RSU grants and settlements are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The terms of the RSU grants, including vesting schedules and settlement procedures, are generally consistent with industry practices.
• Net issuance for tax withholding is a standard practice in RSU settlements to simplify the tax obligations for both the company and the executive.

Stakeholder Impact

• The RSU settlement has a minor impact on shareholders due to the increase in the number of outstanding shares.
• The settlement is a part of the executive compensation plan, impacting the COO's personal financial situation.

Key Dates

Keywords

Restricted Stock Units, RSU Settlement, Beneficial Ownership, Form 4, Leap Therapeutics, LPTX, Insider Trading, Augustine Lawlor, COO, Tax Withholding